Patient preferences for treatment of metastatic melanoma. (29th January 2019)

• Record Type: Journal Article
• Authors: Mansfield, Carol; Ndife, Briana; Chen, Joyce; Gallaher, Kathleen; Ghate, Sameer
• Is Part Of: Future oncology. Volume 15:Number 11(2019)
• Page Start: 1255
• Page End: 1268
• Publication Date: 2019-01-29
• Subjects: adverse effects -- B-RAF -- drug therapy -- immunotherapy -- melanoma -- patient preference -- progression-free survival -- targeted therapy; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0871
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments.Materials & methods: A discrete-choice experiment and best–worst scaling exercise were used to assess relative preferences for treatment attributes.Results: The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a risk profile similar to targeted therapy over a profile similar to immunotherapy, holding efficacy constant.Conclusion: Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.